This site is intended for healthcare professionals
Multiple Sclerosis Resources
Declaration of sponsorship Novartis Pharma AG

Congresses

Declaration of sponsorship Novartis Pharma AG
Read time: 125 mins
Last updated:26th Oct 2022
Published:12th Aug 2021

Novartis has over 80 years of experience in the field of neurosciences, and is committed to developing innovative treatments and improving outcomes for people with MS – view the latest MS data and insights from experts in the Novartis Pharma AG-sponsored congress resources.

  • Your choice of over 80 Novartis Pharma AG-sponsored MS resources from international MS congresses in 2022, 2021 and 2020
  • View and download a diverse selection of oral presentations and ePosters
  • Access core MS data from the ALITHIOS, ASCLEPIOS, EXPAND, and EXCHANGE Phase 3 clinical trials

2022 Congresses – EAN 2022

View or download Novartis Pharma AG-sponsored multiple sclerosis (MS) research from the 8th European Academy of Neurology (EAN), 2022.

  • Study the effect of siponimod on time to wheelchair use in secondary progressive MS
  • Learn COVID-19 outcomes and vaccination in ofatumumab-treated relapsing MS (RMS) patients
  • Review ALITHIOS on long-term efficacy and safety of ofatumumab in RMS

The educational resources below from EAN 2022 focus on high-efficacy treatments (HETs) for MS, ofatumumab and siponimod, as evaluated in the ASCLEPIOS I and II, EXPAND, and ALITHIOS (ongoing) pivotal clinical trials1–3.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

2022 Congresses – AAN 2022

View or download Novartis Pharma AG-sponsored multiple sclerosis (MS) research from the 2022 Annual Meeting of the American Academy of Neurology (AAN).

  • View the latest ofatumumab efficacy and safety data from the ongoing ALITHIOS Phase 3 trial
  • Learn pregnancy and infant outcomes from the Novartis Safety Database in women inadvertently exposed to ofatumumab
  • Discover the study design of the randomised, Phase 3 REMODEL I/II clinical trials

The following resources from AAN 2022 focus on high-efficacy treatments (HETs) for multiple sclerosis (MS), ofatumumab and siponimod, as evaluated in the ALITHIOS (ongoing), ASCLEPIOS I and II, EXPAND, and EXCHANGE (ongoing) pivotal clinical trials1–4.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

2021 Congresses – AAN, ECTRIMS, EAN 2021

Explore the Novartis Pharma AG-sponsored research on multiple sclerosis (MS) presented at leading, MS congresses in 2021.

  • AAN 2021 – Download your choice of the latest subgroup and long-term extension study data from the Phase 3, Novartis Pharma AG-sponsored ASCLEPIOS and EXPAND clinical trials
  • ECTRIMS 2021 – Learn the interactions between fatigue, cognition, pain, and depression in MS, and the Phase 3 NEOS clinical trial study design for paediatric MS
  • EAN 2021 – View the presentation by Trishna Bharadia to deepen your knowledge on what outcomes and measures are most relevant to people living with MS
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

2020 Congresses – AAN, ACTRIMS/ECTRIMS, EAN 2020

Match your own educational objectives with the Novartis Pharma AG-sponsored learning resources below from international 2020 congresses.

  • AAN 2020 – Access long-term data from the core and extension parts of the ASCLEPIOS and EXPAND pivotal trials
  • ACTRIMS/ECTRIMS 2020 – See the PK-B cell model that shows sustained B-cell depletion with the high-efficacy therapy (HET) ofatumumab
  • EAN 2020 – In the ASCLEPIOS and EXPAND Phase 3 clinical trials, view subgroup differences in treatment effects

AAN 2020

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546–557.
  2. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273.
  3. ClinicalTrials.gov. Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS). 2022. https://clinicaltrials.gov/ct2/show/NCT03650114?term=NCT03650114&draw=2&rank=1. Accessed 6 April 2022.
  4. ClinicalTrials.gov. Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod in Advancing RMS Patients (EXCHANGE). 2022. https://clinicaltrials.gov/ct2/show/NCT03623243?term=NCT03623243&draw=2&rank=1. Accessed 6 April 2022.
  5. European Medicines Agency (EMA). Kesimpta®. 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta#product-information-section. Accessed 24 November 2021.
  6. Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2021;13524585211044480.
  7. Saida T, Nakahara J, Sazonov D V., Kurosawa T, Tsumiyama I, Willi R, et al. Sustained Efficacy of Ofatumumab in Relapsing Multiple Sclerosis Patients: Results from Extended Treatment in the Phase 2 APOLITOS Study (2032). Neurology. 2021;96(15 Supplement).
  8. ClinicalTrials.gov. Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS). 2021. https://clinicaltrials.gov/ct2/show/NCT03650114. Accessed 18 November 2021.
  9. ClinicalTrials.gov. Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab (KYRIOS). 2021. https://clinicaltrials.gov/ct2/show/NCT04869358. Accessed 18 November 2021.
  10. European Medicines Agency (EMA). Mayzent®. 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent#product-information-section. Accessed 24 November 2021.
  11. ClinicalTrials.gov. Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS). 2021. https://clinicaltrials.gov/ct2/show/NCT04926818. Accessed 18 November 2021.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: